IgA nephropathy (IgAN), an important cause of kidney failure, is characterized by glomerular IgA deposition and is associated with changes in -glycosylation of the IgA1 molecule. Here, we sought to identify genetic factors contributing to levels of galactose-deficient IgA1 (Gd-IgA1) in white and Chinese populations. Gd-IgA1 levels were elevated in IgAN patients compared with ethnically matched healthy subjects and correlated with evidence of disease progression. White patients with IgAN exhibited significantly higher Gd-IgA1 levels than did Chinese patients. Among individuals without IgAN, Gd-IgA1 levels did not correlate with kidney function. Gd-IgA1 level heritability (h), estimated by comparing midparental and offspring Gd-IgA1 levels, was 0.39. Genome-wide association analysis by linear regression identified alleles at a single locus spanning the gene that strongly associated with Gd-IgA1 level (=0.26; =2.35×10). This association was replicated in a genome-wide association study of separate cohorts comprising 308 patients with membranous GN from the UK (<1.00×10) and 622 controls with normal kidney function from the UK (<1.00×10), and in a candidate gene study of 704 Chinese patients with IgAN (<1.00×10). The same extended haplotype associated with elevated Gd-IgA1 levels in all cohorts studied. encodes a galactosyltransferase enzyme that is important in -galactosylation of glycoproteins. These findings demonstrate that common variation at influences Gd-IgA1 level in the population, which independently associates with risk of progressive IgAN, and that the pathogenic importance of changes in IgA1 -glycosylation may vary between white and Chinese patients with IgAN.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491291PMC
http://dx.doi.org/10.1681/ASN.2016091043DOI Listing

Publication Analysis

Top Keywords

gd-iga1 levels
16
gd-iga1 level
8
genome-wide association
8
gd-iga1
7
levels
5
galactosylation iga1
4
iga1 associated
4
associated common
4
common variation
4
variation iga
4

Similar Publications

A 63-year-old Japanese housewife was admitted to our hospital because of hematuria and proteinuria lasting for 3 months. At the age of 59 years, she was diagnosed with neurosarcoidosis at another hospital, and she received oral glucocorticoid therapy for 1 year. Her serum angiotensin-converting enzyme (ACE) and 1, 25-dihydroxyvitamin D levels were elevated.

View Article and Find Full Text PDF

Introduction: To evaluate the impact of TACI fusion protein (TACI-Ig) on IgA nephropathy (IgAN) in rats, and to explore its mechanism and relationship with TLR4/MyD88/NF-κB pathway.

Method: Sprague Dawley(SD)rats were divided into six groups: control, model, TACI-Ig low dose (TACI-Ig-L), medium dose (TACI-Ig-M), high dose (TACI-Ig-H), and prednisone acetate (PAT) group. The control group and model group received physiological saline injections, while the TACI-Ig groups were administered doses of 7.

View Article and Find Full Text PDF

Therapeutic agents targeting the tumor necrosis factor (TNF) superfamily cytokines B-cell activating factor (BAFF, BLyS) and/or A PRoliferation Inducing Ligand (APRIL) have demonstrated clinical effectiveness in multiple autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, and immunoglobulin A nephropathy (IgAN). However, their clinical utility can often be limited by incomplete and/or prolonged times to clinical response and inconvenient dosing regimens, which may be improved by more potent dual inhibition of both cytokines. Povetacicept (ALPN-303; TACI vTD-Fc) is a crystallizable fragment (Fc) fusion protein of an engineered transmembrane activator and CAML interactor (TACI) domain which mediates more potent inhibitory activity than wild-type TACI-Fc or BAFF- or APRIL-specific antibodies and demonstrates superior pharmacokinetic and pharmacodynamic activity in multiple preclinical disease models.

View Article and Find Full Text PDF
Article Synopsis
  • IgA nephropathy (IgAN) is an immune-related kidney disease caused by the buildup of a specific type of IgA in the kidney glomeruli, leading to various symptoms and a lack of effective treatments due to incomplete understanding of its mechanisms.
  • Recent research identifies the cytokine APRIL as a key player in the production of the problematic IgA1 in IgAN, revealing new potential treatment avenues.
  • Initial studies on APRIL-targeting therapies show promise in reducing harmful protein levels in the urine and improving patient outcomes, suggesting potential new treatments for IgAN.
View Article and Find Full Text PDF

State-of-Art Therapeutics in IgA Nephropathy.

Indian J Nephrol

June 2024

Department of Medicine, Division of Nephrology, University of Alabama, Birmingham, USA.

Article Synopsis
  • - Immunoglobulin-A nephropathy (IgAN) is the leading form of primary glomerulonephritis globally, with about 40% of patients eventually facing end-stage kidney disease (ESKD) within 30 years post-diagnosis due to immune complex formation caused by elevated Gd-IgA1 levels.
  • - Current management focuses on supportive care using medications like renin-angiotensin system inhibitors and sodium-glucose transporter inhibitors to help control proteinuria, with recent advances leading to approvals for new treatments like budesonide and sparsentan.
  • - Ongoing research is exploring novel therapies targeting different pathways involved in IgAN, including those affecting Gd-IgA1 production and the complement system,
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!